Skip to main content

NICE TAs

22/04/2020
TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
22/04/2020
TA556: Darvadstrocel for treating complex perianal fistulas in Crohn's disease
22/04/2020
TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
22/04/2020
TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
22/04/2020
TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
22/04/2020
TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
22/04/2020
TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
22/04/2020
TA582: Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)
22/04/2020
TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast
22/04/2020
TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
22/04/2020
TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
22/04/2020
TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer
22/04/2020
TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
21/04/2020
TA533: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
21/04/2020
TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
21/04/2020
TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
21/04/2020
TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
21/04/2020
TA597: Dapagliflozin with insulin for treating type 1 diabetes
21/04/2020
TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
21/04/2020
TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Follow AWTTC: